BRCA2
HGNC ↗9 article(s) in the watch · Cancer genetics
BRCA2 is a homologous-recombination tumour-suppressor gene. Pathogenic variants raise the risk of breast (female and male), ovarian, prostate and pancreatic cancer and enable access to PARP inhibitors.
Curated publications
Measuring disease likelihood in genomic ascertainment.
Secondary findings in genome sequencing — BRCA1/BRCA2: likelihood of genuine clinical diagnosis
Comprehensive evidence for the pathogenicity of the BRCA2 c.7847C>T (p.Ser2616Phe) variant in Japanese hereditary breast and ovarian cancer.
Hereditary breast and ovarian cancer (HBOC)
The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.
Hereditary prostate cancer predisposition
Comprehensive analysis of BRCA1/2 germline mutations in high-grade prostate cancer among Arab patients.
Hereditary prostate cancer / BRCA1/2
Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey.
Pancreatic adenocarcinoma with germline predisposition
Uptake of cascade tests in relatives of patients undergoing cancer precision medicine in Japan.
Germline variants identified through cancer precision medicine — cascade testing of relatives (BRCA1/2, ATM, MSH2, APC, BAP1, CDK4, CDKN2A, RAD51C)
Decoding the BRCA2 reversion principles underlying PARP inhibitor resistance.
Germline BRCA2 cancer — PARP inhibitor resistance mechanisms through reversion mutations
Surgical Outcomes After Risk-Reducing Mastectomy Among BRCA1 and BRCA2 Carriers
HBOC — surgical safety data for risk-reducing mastectomy
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
gBRCA1/2 breast cancer, early stage (triple negative or luminal)